This website can be best viewed in Microsoft Internet Explorer 9.0+,Chrome,Firefox


  •  
  •  
SlideBar
CAPTCHA
Website Feedback

  1. Members
  2. Service
  3. Meetings/OPD
  4. Teaching & Training
  5. Research
  6. Patient Information
  7. News & Events
  8. Contact Us
Convener : Dr. Tushar Vora ( Medical Oncology )
Secretary : Dr. Siddharth Laskar ( Radiation Oncology )
Medical Oncology
  • Dr. Girish Chinnaswamy
  • Dr. Maya Prasad
Radiation Oncology
  • Dr. Nehal Khanna
Surgical Oncology
  • Dr. Sajid Qureshi
Nuclear Medicine and Molecular Imaging
  • Dr. Sneha Shah
  • Dr. Venkatesh Rangarajan
Radiologist
  • Dr. Seema Kembhavi
  • Dr. Akshay Baheti
  • Dr. Vasundhara Smriti
  • Dr. Kunal Gala
  • Dr. Seema Kembhavi
Physiotherapy
  • Ajeeta Kulkarni
  • Sarika Mahajan
Honorary Ophthalmologist
  • Dr. Nandan Shetye
Pathologist
  • Dr. Mukta Ramadwar
  • Dr. Bharat Rekhi
Palliative Care
  • Dr. Maryann Muckaden
  • Dr. Arun Ghoshal
Department of Anesthesia
Clinical Psychology
  • Dr. Joyita Deodhar
  • Ms. Savita Goswami
Honoroty Endocrinologist
  • Dr. Sudha Rao
Support Group
Trial Coordinator

 

Key Quality Indicators

a) Volume Indicators

Diagnosis

Total
(2016)

Total(2015)

Total(2014)

Neuroblastoma

98

89

77

Renal Tumor

59 (WT 55)

63

54

GCT

48

56

57

Liver tumors

25 (HB 19) 

34 29

Retinoblastoma

52 

56  38

STS

115

140

115

Misc

95

53

97

No malignancy

29

24

19

No investigation

15

25

27

Total

536

541

513

 

b) Drop out rate : 2.7 % ( 15 out of 536) (2015- 4.6 %)
c) Time to first JC: 0-3 days
d) Time for decision making : 7-14 days

e) Surgeries performed

 

TMH

ACTREC

Total(2016)

Total(2015)

Major      

158

Minor      

65

Pediatric vascular access      

50

Adult vascular access       27
Total       300

 

f) Radiotherapy given : (EBRT + Brachy = 180) 

Treatment

No of Patients

 RT Intent (Ext. RT)  Radical  122/169 (72%)
   Palliative  26/169 (15%)
   Ketlar  35/169 (21%)
 Ext RT  158/180 (88%)
 Brachytherapy  11/180 (06%)
 Conventional  81/169 (48%)
 3D-CRT/ IMRT  88/169 (52%)
 Turnaround Time (Appt. Visit to Start)  Mean: 54.8 Days
     Median: 50.2 Days
     Range: 0-147 ays
Did not come for RT after Appt. 05/169 (03%)
Did not complete planned RT 02/169 (1.2%)
Post RT follow up visit in RT OPD -
Referred outside for RT 156

 

 g) After Completion of Therapy (ACT) Clinic for long-term survivors of childhood cancers.

 

2016

2015

Follow-up

794

655

New registration 60 90
Total 854 745

 

h) Paediatric palliative care new registrations – 301 (inclusive of all DMGs seeing paediatric
patients like PHL, BST, etc) 

 

 

b) Outcome Indicators: Morbidity and mortality

 Treatment

Morbidity

Mortality

Surgery

30 day – 12.1 % (27/233)

0.4 % (1/223)

Chemotherapy Need for admission for 1.8% (8/443)
  Febrile neutropenia 7.2%
(32/ 443)
 
Radiotherapy
(n=169)
Acute toxicity
Grade I: 30%
Grade II: 05%
Grade III: 04%
0 %

 

c) Outcome Indicators: survival rates

Cancer

Event-free
survival (%) TMC

Overall
survival
(%)TMC

From
Published data
(%)

Wilms

 84 

89 

90(OS)

Germ cell tumors
(extracranial)
81 93 Best – 95 OS
 Retinoblastoma 79  81 95 OS
Soft tissue sarcomas (non-
rhabdomyosarcoma)
61 77 89 OS
Neuroblastoma
( Low/Intermediate)
68 75

54-100 (4 year

EFS)

Neuroblastoma (High risk)  22 40 30-50 ( 3year
EFS)
Extraskeletal Ewing’s
Sarcoma
68 77 69–77 and
58–67 EFS and
OS
Hepatoblastoma 70 88 100,83,56 and
46 – stage wise
OS

 

 

d) Process Indicator
Compliance to time lines: in patients who have completed entire therapy (a range is given as
multiple tumor types are considered)
Date of registration to start of treatment in 14 days: 85-90%
Getting surgery within expected dates from induction chemotherapy: 65-87%

Completion of entire therapy at expected time for tumor and stage: 93-94%



OPD Timings

General OPD - All Days Except Saturdays
Timing - 09:15-17:30 Hours
Location - Main Building, Ground Floor , Room No.88 .

Priviate OPD - All Days Except Saturdays
Timing - 09:15-17:30 Hours
Location - Main Building, Ground Floor , Room No.88.

Meetings

 

Meeting

Days

Incharge

OPD timings

All working days

All clinicians

Surgery days

Every Monday,
Wednesday and Friday

Dr. Sajid Qureshi

Patient Discussion Joint meeting

Every Tuesdays &
Thursdays

Dr. Sajid Qureshi

ACT clinic

Every Tuesday and
Wednesday

Dr. Maya Prasad

Pediatric Palliative Care OPD

Tuesday and Thursday
2.00 – 5.30 pm

Dr. Naveen Salins

Administrative Meeting

2nd Wednesday

Dr. Seema Kembhavi

Morbidity & Mortality Meeting

2nd Tuesdays

Dr. Sajid Qureshi

Academic Meeting

Tuesdays

 

Dr. TusharVora

Social Support Group Meeting

Every Tuesdays

Dr. TusharVora

All meeting were held regularly and had adequate quorum of atleast one pediatric oncologist, pediatric surgeon, pediatric radiation oncologist, pathologist and radiologist. Social Support Group meetings are attended by Medical Social Workers & volunteers.

Progress

International collaborations of the DMG

1.Pilot and Phase II study of immunotherapy with anti-GD2 antibody in high risk
neuroblastoma children.

High risk neuroblastoma in children has an unfavourable outcome in spite of multimodality therapy including high dose chemotherapy with ABMT. Over the last decade significant improvements in outcomes have been documented in high risk neuroblastoma children with the use of anti-GD2 antibody. This antibody is  resently not available in India. On collaboration with Memorial Sloan Kettering Cancer Centre, New York, a pilot study is being initiated to start anti-GD2 immunotherapy for high risk neuroblastoma children in TMC. The study is approved by ethics committee, received funding and waiting regulatory approval by the DGCI.

2.AGCT 1531; Reduction in therapy for low and intermediate risk extracranial germ cell
tumors (MaGIC consortium study-Malignant Germ Cell Tumors International Consortium)

This is a collaborative study with the children Oncology group of USA. The study is randomised to compare the efficacy and toxicity of Cisplatin and carboplatin for low and intermediate risk GCTs along with reduction in therapy for the low risk disease. The study protocol is now finalised and is now undergoing regulatory approvals in United States after which a formal MOU will be signed between TMC and COG.

Publications (2016)

 1: Qureshi SS, Bhagat M, Anam J, Vora T.
Aggressive cervical neuroblastoma with a rare paraneoplastic syndrome: A therapeutic dilemma.
J Indian Assoc Pediatr Surg. 2016 Oct-Dec;21(4):181-183. PubMed PMID: 27695211;
PubMed Central PMCID: PMC4980880.


2: Prabhu A, Bhagat M, Ramadwar M, Qureshi SS.
Pancreatoblastoma masquerading as hepatoblastoma: A diagnostic dilemma.
J Indian Assoc Pediatr Surg. 2016 Apr-Jun;21(2):84-6. doi: 10.4103/0971-9261.176969.
PubMed PMID: 27046982; PubMed Central PMCID: PMC4790136.

3: Pareekutty NM, Bhagat M, Vora T, Qureshi SS.
Rhabdomyosarcoma of the breast: Report of two cases with the review of literature.
J Indian Assoc Pediatr Surg.2016 Apr-Jun;21(2):81-3. doi: 10.4103/0971-9261.176964.
PubMed PMID: 27046981;PubMed Central PMCID: PMC4790135.

4: Qureshi SS, Rent EG, Bhagat M, Dsouza P, Kembhavi S, Vora T, Prasad M,
Chinnaswamy G, Ramadwar M, Laskar S, Khanna N, Shah S, Talole S. Chyle leak following surgery for abdominal neuroblastoma.
J Pediatr Surg. 2016 Sep;51(9):1557-60. doi: 10.1016/j.jpedsurg.2015.11.002. PubMed
PMID: 26656616.

5.: Gota V, Chinnaswamy G, Vora T, Rath S, Yadav A, Gurjar M, Veal G, Kurkure P.
Pharmacokinetics and pharmacogenetics of 13-cis retinoic acid in Indian high-risk neuroblastoma patients.
Cancer Chemother Pharmacol. 2016 Oct;78(4):763-8. doi: 10.1007/s00280-016-3126-3. PubMed PMID: 27541143.

6: Gupta S, Aitken JF, Bartels U, Brierley J, Dolendo M, Friedrich P,
Fuentes-Alabi S, Garrido CP, Gatta G, Gospodarowicz M, Gross T, Howard SC, Molyneux E, Moreno F, Pole JD, Pritchard-Jones K, Ramirez O, Ries LA, Rodriguez-Galindo C, Shin HY, Steliarova-Foucher E, Sung L, Supriyadi E, Swaminathan R, Torode J, Vora T, Kutluk T, Frazier AL. Paediatric cancer stage in population-based cancer registries: the Toronto consensus principles and guidelines.
Lancet Oncol. 2016 Apr;17(4):e163-72. doi: 10.1016/S1470-2045(15)00539-2. Review. PubMed PMID: 27300676.

7: Indelicato DJ, Merchant T, Laperriere N, Lassen Y, Vennarini S, Wolden S,
Hartsell W, Pankuch M, Brandal P, Law CC, Taylor R, Laskar S, Okcu MF, Bouffet E, Mandeville H, Björk-Eriksson T, Nilsson K, Nyström H, Constine LS, Story M, Timmermann B, Roberts K, Kortmann RD. Consensus Report From the Stockholm Pediatric Proton Therapy Conference. Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2):387-92. doi: 10.1016/j.ijrobp.2016.06.2446. PubMed PMID: 27598806.

8: Damani A, Salins N, Ghoshal A, Muckaden M. Specialist Pediatric Palliative
Care Prescribing Practices: A Large 5-year Retrospective Audit. Indian J Palliat Care. 2016 Jul-Sep;22(3):274-81. doi: 10.4103/0973-1075.185033. PubMed PMID: 27559255; PubMed Central PMCID: PMC4973487.

9: Ghoshal A, Salins N, Damani A, Deodhar J, Muckaden M.
Specialist Pediatric Palliative Care Referral Practices in Pediatric Oncology: A Large 5-year

Retrospective Audit. Indian J Palliat Care. 2016 Jul-Sep;22(3):266-73. doi:10.4103/0973-1075.185031. PubMed PMID: 27559254; PubMed Central PMCID:PMC4973486.

10: Salins N, Patra L, Usha Rani MR, Lohitashva SO, Rao R, Ramanjulu R, Vallath
N. Integration of Early Specialist Palliative Care in Cancer Care: Survey of Oncologists, Oncology Nurses, and Patients. Indian J Palliat Care. 2016

Jul-Sep;22(3):258-65. doi: 10.4103/0973-1075.185030. PubMed PMID: 27559253;
PubMed Central PMCID: PMC4973485.

11: Ghoshal A, Salins N, Deodhar J, Damani A, Muckaden MA. Fatigue and Quality of
Life Outcomes of Palliative Care Consultation: A Prospective, Observational Study in a Tertiary Cancer Center. Indian J Palliat Care. 2016 Oct-Dec;22(4):416-426.
PubMed PMID: 27803563; PubMed Central PMCID: PMC5072233.

12: Salins N, Ramanjulu R, Patra L, Deodhar J, Muckaden MA. Integration of Early
Specialist Palliative Care in Cancer Care and Patient Related Outcomes: A Critical Review of Evidence. Indian J Palliat Care. 2016 Jul-Sep;22(3):252-7.
doi: 10.4103/0973-1075.185028. PubMed PMID: 27559252; PubMed Central PMCID: PMC4973484.

13: Salins N, Deodhar J, Muckaden MA. Intensive Care Unit death and factors
influencing family satisfaction of Intensive Care Unit care. Indian J Crit Care Med. 2016 Feb;20(2):97-103. doi: 10.4103/0972-5229.175942. Review. PubMed PMID: 27076710; PubMed Central PMCID: PMC4810940.

14: Dhiliwal S, Salins N, Deodhar J, Rao R, Muckaden MA. Pilot Testing of Triage
Coding System in Home-based Palliative Care Using Edmonton Symptom Assessment Scale. Indian J Palliat Care. 2016 Jan-Mar;22(1):19-24. doi:10.4103/0973-1075.173943. PubMed PMID: 26962276;

PubMed Central PMCID:PMC4768444.

15: Ghoshal A, Salins N, Damani A, Deodhar J, Muckaden MA. Medical Management of
Pediatric Malignant Bowel Obstruction in a Patient with Burkitt's Lymphoma and Ataxia Telangiectasia Using Continuous Ambulatory Drug Delivery System.

J Pain Palliat Care Pharmacother. 2016;30(1):44-8. doi: 10.3109/15360288.2015.1134748.
PubMed PMID: 26862790.

Text book chapters: --

Achievements of Members

Dr. Sajid Qureshi
1. K.M. Yusuf Memorial Oration – Tamil Nadu & Pondicherry Paediatric Surgeons Annual
Conference, Chennai, Tamil Nadu June 2015.
2. Executive Committee Member- International Society of Pediatric Surgical Oncology.
Dr. G. Chinnaswamy
1. Chair, Solid tumour working group, Paediatric Oncology East and Mediterranean
(POEM)
Dr. Maya Prasad
1. Associate editor, Pediatric Hematology and Oncology Journal
2. Chair of Rare Tumour Working Group, InPOG (collaborative research group of
Paediatric Haematology- Oncology Chapter of Indian Academy of Paediatrics)
Dr. Tushar Vora
1. Chair, Osteosarcoma Working Group, InPOG
Dr. Seema Kembhavi
1. Member, Liver tumor Working group (InPOG)
2. Reviewer Indian Journal of Radiology and Imaging (IJRI)
Dr. Siddhartha Laskar
1. Chair, Sarcoma Working group (InPOG)
Dr. M.Mukaden
1. President Elect of Indian Association of Palliative Care to take over from Feb 2016
Dr. Naveen Salins
1. Editor of Indian Journal of Palliative Care
2. Visiting Associate Professor, Northern Adelaide Palliative Services, Modbury Hospital
3. Secured PhD palliative care position in Lancaster University, UK.

Projects

  • 1 Study of Nutritional Assessment and Quality of Life in Children Receiving Radiation Therapy. Project no. 531. Principal Investigator- Dr. SiddharthLaskar
  • 2Evaluation of a novel COMBAT (combined and metronomic, biological and traditional therapy) approach for the treatment of newly diagnosed, metastatic Ewing’s family of tumors and rhabdomyosarcomas: Project no. 498. Principal Investigator- Dr. TusharVora
  • 3To assess the role of whole body FDG PET/CT in the metastatic staging of Ewings family of tumors. Project no. 729. Principal Investigator-Sneha Shah
  • 4 Evaluation of VEGF expression of tumor cells as a potential prognostic marker in Ewing’s sarcoma. Project no. 778 Principal Investigator -JyotiBajpai
  • 5Prospective study of customized approach for unilateral Wilms tumor. Project no.913. Principal Investigator – Dr Sajid Qureshi
  • 6A prospective study of sentinel lymph node biopsy for extremity sarcomas with propensity for lymphatic metastases using indigenous gamma probe for Tc 99m sulphur colloid and blue dye. Project no. 557. Principal Investigator – Dr Sajid Qureshi
  • 7Prospective randomized trial of prophylaxis with single dose intravenous amikacin with 3-days cefuroxime + amikacin (+ metronidazole) in pediatric oncosurgery. Project no.388. Principal Investigator – Dr Sajid Qureshi. Study terminated due to high infection rate in the study arm.
  • 8To evaluate the role of PET-CT Scan in staging of Paediatric round cell tumors. Can it eliminate the need for Bone marrow biopsy? Project no. 1161. Principal Investigator – Dr Sajid Qureshi
  • 9Standardization and validation of protocols for long and short term storage of biological materials in tissue repository. Project no. 370 Principal Investigator: Dr M K Amin/Dr.S.Qureshi
  • 10Image guided intensity modulated helical tomotherapy (IG-IMHT) for children and adults with rhabdomyosarcoma Project no. 499 Principal Investigator: Dr. SidharthLaskar.
  • 11Whole Body MRI in small round cell tumors. Project no. 625. Principal Investigator: Dr. Seema Kembhavi
  • 12IAEA CRP on Optimisation of Radiotherapy in Low Resource Settings: Paediatric Cancer Patients (2008-2012) Project no. 794. Principal Investigator: Dr. Sidharth Laskar.
  • 13Optimizing Therapy For Nasopharyngeal Carcinoma In Children Using Physical & Biological Parameters: A Phase II Single Arm Study of Intensity Modulated Radiation Therapy (IMRT) in Nasopharyngeal Carcinoma of children.Project No359 Principal Investigator : Dr.S.Laskar
  • 14Pharmacokinetics and pharmacogenetic study of 13-cis-retinoic acid in Indian children with high-risk neuroblastoma. Project no 716 Principal Investigator : DrPurnaKurkure, Dr.VikramGota
  • 15A Prospective Study Of Concurrent Carboplatin And Radiotherapy Followed By Adjuvant Chemotherapy In Patients With Newly Diagnosed High Risk Central Nervous System Embryonal Tumors. Project no200 Principal Investigator : Dr.PurnaKurkure
  • 16Evaluation of stem cells in testicular biopsies of young adult survivors of childhood cancer. Project no 789 Principal Investigator : Dr.PurnaKurkure
  • 17Role of plasma BNP (Brain, natriuretic peptide) levels as a screening test for anthracycline induced cardiotoxicity:a pilot study. Project no 483 Principal Investigator : Dr.ArunaAlahari / Dr.PurnaKurkure
  • 18The risk of hepatocellular carcinoma in patients with chronic liver disease of viral etiology and iron deficiency. Project no 487 Principal Investigator Dr.PrachiPatil / Dr.PurnaKurkure
  • 19A Phase IIb, Partially-Blinded, Randomized, Active Comparator-Controlled Study to Evaluate the Pharmacokinetics/Pharmacodynamics, Safety, and Tolerability of Fosaprepitant in Pediatric Patients for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated with Emetogenic Chemotherapy” P.no. 1238. Principal Investigator : Dr.ShripadBanavali
  • 20A phase I/II study of sunitinib in young patients with advanced gastrointestinal stromal tumor project no.1254. Principal Investigator: Dr.PurnaKurkure
  • 21The role of Retroperitoneal lymph node dissection (RPLND) in Intermediate and high risk Neuroblastoma patients Project no. 1261. Principal Investigator – Dr Sajid Qureshi
  • 22The impact of Optic Nerve tumor free resection margin on survival in Retinoblastoma”. Project no. 1265. Principal Investigator – Dr Sajid Qureshi
  • 23Malignant salivary gland tumors in Indian pediatric population: clinical experience of a tertiary care cancer hospital Project no. 1477. Principal Investigator – Dr Sajid Qureshi
  • 24Retrospective study of complications related to totally implantable venous access devises.” Project no. 1561. Principal Investigator – Dr Sajid Qureshi
  • 25Translation and validation of PedsQL 3.0 Cancer module into Indian language (Marathi & Hindi) to study Quality of Life of pediatric solid tumor patients from a tertiary care cancer centre.” Project no. 1540. Principal Investigator – Dr Sajid Qureshi
  • 26Prognostication in neuroblastoma by detection of MYCN amplification by fluorescent and chromogenic in situ hybridization, quantitative and qualitative PCR analysis Project no. 624. Principal Investigator – Dr Mukta Ramadwar

Events in 2016/2017

ImPaCCT Foundation School Program

  • Birthday Party
  • Birthday Party

Annual event Hope 2016

  • img1
  • img2
  • img3

Pediatric Birthday celebrations

  • Annual Art workshops for children- December 2012
  • Annual Art workshops for children- December 2012

Moscow Trip 2017

  • Lior Suchard Show for Children on 1st May, 2012
  • Lior Suchard Show for Children on 1st May, 2012
  • Lior Suchard Show for Children on 1st May, 2012

Parent Support Group Meetings

  • Annual Child hood cancer Survivor day UGAM-3rd June 2012

OPD workshops

  • img1
  • img2

Visit by the Clown

  • img1
  • img2

2nd Annual Paediatric Workshop-2017

  • img1
  • img2
  • img3
  • img4

TYCON Conference-2017

  • img1
  • img2

Phone: Department Office Number: (+9122) 24177000 / Ext.No.- 4180

Address: Department of Pediatric Solid Tumours,  

TATA MEMORIAL HOSPITAL, Dr.E.Borges Road, Parel, Mumbai-400-012

Maharashtra, India

Fax: Hospital Fax Number: (+9122) 24146392

Email-id: Email-id: dmgpae@tmc.gov.in

Contact Us

TATA MEMORIAL HOSPITAL
Dr. E Borges Road, Parel, Mumbai - 400 012 India
Phone: +91-22- 24177000, 24146750 - 55
Fax: +91-22-24146937
E-mail : msoffice@tmc.gov.in (for patient care and queries) / hrd@tmc.gov.in(for administrative - HRD matters)

628717 (20)